PT1077957E - Derivados do acido oxi-iminoalcanoico - Google Patents

Derivados do acido oxi-iminoalcanoico

Info

Publication number: PT1077957E
Authority: PT; Portugal
Prior art keywords: iminoalcanoic; oxy; acid derivatives; derivatives; acid
Prior art date: 1998-05-11

Application number

PT99918355T

Other languages

English (en)

Inventor

Hiroyuki Odaka

Yu Momose

Hiroshi Imoto

Hiroyuki Kimura

Junichi Sakamoto

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-11

Filing date

1999-05-10

Publication date

2004-10-29

1999-05-10 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2004-10-29 Publication of PT1077957E publication Critical patent/PT1077957E/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

PT99918355T 1998-05-11 1999-05-10 Derivados do acido oxi-iminoalcanoico PT1077957E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP12792198		1998-05-11
JP12792298		1998-05-11

Publications (1)

Publication Number	Publication Date
PT1077957E true PT1077957E (pt)	2004-10-29

Family

ID=26463748

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT99918355T PT1077957E (pt)	1998-05-11	1999-05-10	Derivados do acido oxi-iminoalcanoico

Country Status (27)

Country	Link
US (3)	US6251926B1 (pt)
EP (2)	EP1077957B1 (pt)
JP (1)	JP2000198772A (pt)
KR (1)	KR100388120B1 (pt)
CN (1)	CN1148361C (pt)
AR (1)	AR029876A1 (pt)
AT (1)	ATE272625T1 (pt)
AU (1)	AU766831B2 (pt)
BR (1)	BR9910371A (pt)
CA (1)	CA2331879A1 (pt)
CO (1)	CO5040066A1 (pt)
DE (1)	DE69919156T2 (pt)
ES (1)	ES2226377T3 (pt)
HK (1)	HK1034972A1 (pt)
HU (1)	HUP0103714A3 (pt)
ID (1)	ID28699A (pt)
IL (1)	IL139470A0 (pt)
LV (1)	LV12606B (pt)
MY (1)	MY123337A (pt)
NO (1)	NO317426B1 (pt)
NZ (1)	NZ508066A (pt)
PE (1)	PE20000625A1 (pt)
PL (1)	PL344002A1 (pt)
PT (1)	PT1077957E (pt)
RU (1)	RU2213738C2 (pt)
SK (1)	SK16412000A3 (pt)
WO (1)	WO1999058510A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL344002A1 (en) *	1998-05-11	2001-09-10	Takeda Chemical Industries Ltd	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
TWI249401B (en) *	1999-04-14	2006-02-21	Takeda Chemical Industries Ltd	Agent for improving ketosis
WO2001016120A1 (en)	1999-08-27	2001-03-08	Eli Lilly And Company	Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
DE19948126A1 (de) *	1999-10-06	2001-04-12	Max Delbrueck Centrum	Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
CA2389208A1 (en) *	1999-10-29	2001-05-10	Takeda Chemical Industries, Ltd.	Process for the preparation of oxyiminoalkanoic acid derivatives
AR031078A1 (es) *	1999-10-29	2003-09-10	Takeda Pharmaceutical	Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
PL356745A1 (en) *	1999-11-10	2004-06-28	Takeda Chemical Industries, Ltd	Body weight gain inhibitors
WO2001034579A1 (fr) *	1999-11-10	2001-05-17	Takeda Chemical Industries, Ltd.	Derives d'acide alcoxyiminoalcanoique
JP3723071B2 (ja)	1999-11-10	2005-12-07	武田薬品工業株式会社	含窒素５員複素環化合物
EP1277730A4 (en) *	2000-03-28	2005-03-16		HEMMER OF NEOVASCULARIZATION
WO2002014291A1 (en) *	2000-08-11	2002-02-21	Nippon Chemiphar Co.,Ltd.	PPARδ ACTIVATORS
US20060089389A1 (en) *	2000-08-22	2006-04-27	Malcolm Allison	Combination
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EP1357115B1 (en)	2000-12-28	2009-06-17	Takeda Pharmaceutical Company Limited	Alkanoic acid derivatives, process for their production and use thereof
EP1394154A4 (en) *	2001-03-23	2005-05-18	Takeda Pharmaceutical	HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
DE60237594D1 (de) *	2001-04-25	2010-10-21	Takeda Pharmaceutical	Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
WO2003059372A2 (en) *	2001-12-29	2003-07-24	Novo Nordisk A/S	Combined use of a glp-1 compound and a modulator of diabetic late complications
TWI343915B (en) *	2002-10-07	2011-06-21	Hoffmann La Roche	Chirale ppar agonists
US8168233B2 (en) *	2002-10-18	2012-05-01	Amylin Pharmaceuticals, Inc.	Treatment of pancreatitis with amylin
CA2505322A1 (en)	2002-11-08	2004-05-21	Takeda Pharmaceutical Company Limited	Receptor function regulator
AU2003297062A1 (en) *	2002-12-11	2004-06-30	University Of Massachusetts	METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
ATE551056T1 (de) *	2002-12-27	2012-04-15	Takeda Pharmaceutical	Mittel zur hemmung der körpergewichtszunahme
JP5140881B2 (ja) *	2003-09-17	2013-02-13	要川杉	医薬組成物
JP4740884B2 (ja) *	2004-02-24	2011-08-03	アイアールエム・リミテッド・ライアビリティ・カンパニー	免疫抑制性化合物および組成物
CA2560928A1 (en) *	2004-03-29	2005-10-06	Sankyo Company Limited	Therapeutic agent for diabetes containing insulin resistance improving agent
US7517910B2 (en)	2004-03-30	2009-04-14	Takeda Pharmaceutical Company Limited	Alkoxyphenylpropanoic acid derivatives
EP1750862B1 (en)	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
KR20070053283A (ko) *	2004-09-13	2007-05-23	산텐 세이야꾸 가부시키가이샤	각결막장해 치료제
US7556933B2 (en) *	2004-10-01	2009-07-07	Luminultra Technologies Ltd.	Reagent system and process for adenosine triphosphate monitoring
EP2308839B1 (en)	2005-04-20	2017-03-01	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds
EP1876179B1 (en)	2005-04-28	2015-03-25	Takeda Pharmaceutical Company Limited	Thienopyrimidone compounds
WO2006126514A1 (ja)	2005-05-27	2006-11-30	Shionogi & Co., Ltd.	イソキサゾール骨格を有するアリール酢酸誘導体
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US7491414B2 (en) *	2005-10-12	2009-02-17	Gaia Herbs, Inc.	Anti-inflammatory substances extracted from Echinacea
JPWO2008136428A1 (ja)	2007-04-27	2010-07-29	武田薬品工業株式会社	含窒素５員複素環化合物
EP2266983B1 (en)	2008-04-16	2013-06-05	Takeda Pharmaceutical Company Limited	Nitrogenated 5-membered heterocyclic compound
WO2010011302A1 (en) *	2008-07-22	2010-01-28	Chdi, Inc.	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JPWO2010016552A1 (ja)	2008-08-07	2012-01-26	武田薬品工業株式会社	過敏性腸症候群治療薬
CA2782776A1 (en)	2008-12-04	2010-06-10	Ikfe Gmbh	Biomarkers for atherosclerosis
US20110118134A1 (en)	2008-12-11	2011-05-19	Ikfe Gmbh	Biomarkers for insulin sensitizer drug response
WO2010076655A1 (en)	2008-12-30	2010-07-08	Ikfe Gmbh	Biomarkers for adipose tissue activity
US20100210541A1 (en)	2009-01-07	2010-08-19	Andreas Pfuetzner	Biomarkers for Appetite Regulation
CN102875548A (zh) *	2011-07-14	2013-01-16	中国科学院大连化学物理研究所	一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法
CN103827095A (zh)	2011-08-30	2014-05-28	Chdi基金会股份有限公司	犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
US9981918B2 (en)	2011-08-30	2018-05-29	Chdi Foundation, Inc.	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
WO2014007228A1 (ja)	2012-07-03	2014-01-09	小野薬品工業株式会社	ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
BR112016007078A2 (pt)	2013-09-30	2017-12-12	Ono Pharmaceutical Co	composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
WO2015107541A1 (en) *	2013-12-16	2015-07-23	Cadila Healthcare Limited	Oximino derivatives for the treatment of dyslipidemia
CR20170061A (es)	2014-07-17	2017-07-17	Chdi Foundation Inc	Métodos y composiciones para el tratamiento de trastornos relacionados con vih
FR3042903B1 (fr) *	2015-10-21	2017-12-08	Commissariat Energie Atomique	Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
TW201835081A (zh)	2017-02-08	2018-10-01	日商小野藥品工業股份有限公司	具有體抑素受體促效活性之化合物及其醫藥用途
US11109683B2 (en)	2019-02-21	2021-09-07	Steelcase Inc.	Body support assembly and method for the use and assembly thereof
US11357329B2 (en)	2019-12-13	2022-06-14	Steelcase Inc.	Body support assembly and methods for the use and assembly thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU177578B (en)	1976-08-27	1981-11-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
JPS5849382A (ja)	1981-09-18	1983-03-23	Kyowa Hakko Kogyo Co Ltd	β−ラクタム化合物
JPS59167576A (ja)	1983-03-15	1984-09-21	Kyowa Hakko Kogyo Co Ltd	β−ラクタム化合物
JPS6277391A (ja)	1984-12-21	1987-04-09	Mochida Pharmaceut Co Ltd	セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
JPS62158290A (ja) *	1985-12-28	1987-07-14	Banyu Pharmaceut Co Ltd	新規セフアロスポリン誘導体
US4698338A (en)	1986-02-19	1987-10-06	Eli Lilly And Company	7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins
US5750532A (en) *	1986-12-10	1998-05-12	Schering Corporation	Pharmaceutically active compounds
JPH0277391A (ja)	1988-09-14	1990-03-16	Suzuki Motor Co Ltd	水ジェット推進船のビルジ水排水装置
ES2118769T3 (es)	1988-11-21	1998-10-01	Zeneca Ltd	Fungicidas.
EP0400805A1 (en)	1989-04-25	1990-12-05	Toshiyasu Ishimaru	Cephalosporin compounds and their use
JPH03115272A (ja) *	1989-10-19	1991-05-16	Banyu Pharmaceut Co Ltd	マンデル酸誘導体およびその製法
FI912873A (fi) *	1990-06-18	1991-12-19	Fujisawa Pharmaceutical Co	Ny polypeptidfoerening och foerfarande foer dess framstaellning.
ES2120100T3 (es) *	1990-06-27	1998-10-16	Basf Ag	O-bencil-oximeteres y agentes protectores de las plantas que contienen estos compuestos.
JPH04112890A (ja) *	1990-09-04	1992-04-14	Ajinomoto Co Inc	新規チアゾール誘導体及び該誘導体を含有する抗菌剤
EP0486011A3 (en) *	1990-11-16	1992-07-15	Fujisawa Pharmaceutical Co., Ltd.	Pharmaceutical composition against pneumocystis carinii
CA2100918C (en) *	1992-07-21	1997-01-21	Nobuyuki Hamanaka	Oxime derivative
US5512581A (en) *	1994-07-18	1996-04-30	Abbott Laboratories	Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
CA2159938A1 (en)	1994-10-07	1996-04-08	Hiroaki Yanagisawa	Oxime derivatives, their preparation and their therapeutic use
CH689228A5 (de)	1994-10-07	1998-12-31	Novartis Ag	Oximether, sowie diese enthaltende Pflanzenschutzmittel.
US5902726A (en)	1994-12-23	1999-05-11	Glaxo Wellcome Inc.	Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en)	1995-04-25	2000-02-08	The Salk Institute For Biological Studies	Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
AU5701896A (en) *	1995-06-02	1996-12-18	Sankyo Company Limited	Aromatic oxyimino derivatives
US5939442A (en)	1995-06-07	1999-08-17	The Salk Institute For Biological Studies	Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
FR2737893B1 (fr) *	1995-08-16	1997-09-12	Roussel Uclaf	Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments
GB9600464D0 (en)	1996-01-09	1996-03-13	Smithkline Beecham Plc	Novel method
GB9604242D0 (en)	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JPH09323929A (ja)	1996-04-02	1997-12-16	Sankyo Co Ltd	オキシム誘導体を含有する医薬
DK0916651T3 (da)	1996-04-04	2003-12-01	Sankyo Co	Phenylalkylcarboxylsyrederivater
WO1998005331A2 (en)	1996-08-02	1998-02-12	Ligand Pharmaceuticals Incorporated	Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
JP4427825B2 (ja)	1997-07-24	2010-03-10	アステラス製薬株式会社	コレステロール低下作用を有する医薬組成物
JPH11193272A (ja)	1997-10-01	1999-07-21	Sankyo Co Ltd	フェニルアルキルカルボン酸誘導体を含有する医薬
PL344002A1 (en) *	1998-05-11	2001-09-10	Takeda Chemical Industries Ltd	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

1999
- 1999-05-10 PL PL99344002A patent/PL344002A1/xx not_active Application Discontinuation
- 1999-05-10 IL IL13947099A patent/IL139470A0/xx unknown
- 1999-05-10 ES ES99918355T patent/ES2226377T3/es not_active Expired - Lifetime
- 1999-05-10 MY MYPI99001832A patent/MY123337A/en unknown
- 1999-05-10 BR BR9910371-0A patent/BR9910371A/pt not_active IP Right Cessation
- 1999-05-10 SK SK1641-2000A patent/SK16412000A3/sk unknown
- 1999-05-10 AR ARP990102190A patent/AR029876A1/es unknown
- 1999-05-10 RU RU2000131183/04A patent/RU2213738C2/ru not_active IP Right Cessation
- 1999-05-10 PT PT99918355T patent/PT1077957E/pt unknown
- 1999-05-10 CN CNB998060070A patent/CN1148361C/zh not_active Expired - Fee Related
- 1999-05-10 AU AU36297/99A patent/AU766831B2/en not_active Ceased
- 1999-05-10 US US09/423,854 patent/US6251926B1/en not_active Expired - Fee Related
- 1999-05-10 DE DE69919156T patent/DE69919156T2/de not_active Expired - Lifetime
- 1999-05-10 NZ NZ508066A patent/NZ508066A/xx unknown
- 1999-05-10 AT AT99918355T patent/ATE272625T1/de not_active IP Right Cessation
- 1999-05-10 WO PCT/JP1999/002407 patent/WO1999058510A1/en not_active Application Discontinuation
- 1999-05-10 HU HU0103714A patent/HUP0103714A3/hu unknown
- 1999-05-10 CA CA002331879A patent/CA2331879A1/en not_active Abandoned
- 1999-05-10 EP EP99918355A patent/EP1077957B1/en not_active Expired - Lifetime
- 1999-05-10 KR KR10-2000-7000081A patent/KR100388120B1/ko not_active IP Right Cessation
- 1999-05-10 EP EP04075569A patent/EP1428531A1/en not_active Withdrawn
- 1999-05-10 ID IDW20002324A patent/ID28699A/id unknown
- 1999-05-11 PE PE1999000393A patent/PE20000625A1/es not_active Application Discontinuation
- 1999-05-11 CO CO99029123A patent/CO5040066A1/es unknown
- 1999-12-28 JP JP11373202A patent/JP2000198772A/ja active Pending
2000
- 2000-11-01 LV LVP-00-148A patent/LV12606B/en unknown
- 2000-11-02 NO NO20005531A patent/NO317426B1/no unknown
- 2000-11-16 US US09/714,699 patent/US6495581B1/en not_active Expired - Fee Related
2001
- 2001-08-15 HK HK01105750A patent/HK1034972A1/xx not_active IP Right Cessation
2002
- 2002-12-27 US US10/331,056 patent/US6924300B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69919156T2 (de)	2005-11-03
US6924300B2 (en)	2005-08-02
US20030186985A1 (en)	2003-10-02
HUP0103714A2 (hu)	2002-01-28
HUP0103714A3 (en)	2003-05-28
HK1034972A1 (en)	2001-11-09
EP1428531A1 (en)	2004-06-16
AU3629799A (en)	1999-11-29
CO5040066A1 (es)	2001-05-29
RU2213738C2 (ru)	2003-10-10
LV12606A (lv)	2001-01-20
PE20000625A1 (es)	2000-07-24
EP1077957A1 (en)	2001-02-28
LV12606B (en)	2001-05-20
KR100388120B1 (ko)	2003-06-18
KR20010021523A (ko)	2001-03-15
BR9910371A (pt)	2001-01-09
US6251926B1 (en)	2001-06-26
AU766831B2 (en)	2003-10-23
CN1148361C (zh)	2004-05-05
AR029876A1 (es)	2003-07-23
ID28699A (id)	2001-06-28
NO20005531L (no)	2001-01-05
DE69919156D1 (de)	2004-09-09
NZ508066A (en)	2003-03-28
ATE272625T1 (de)	2004-08-15
EP1077957B1 (en)	2004-08-04
WO1999058510A1 (en)	1999-11-18
NO20005531D0 (no)	2000-11-02
NO317426B1 (no)	2004-10-25
ES2226377T3 (es)	2005-03-16
PL344002A1 (en)	2001-09-10
MY123337A (en)	2006-05-31
SK16412000A3 (sk)	2001-08-06
US6495581B1 (en)	2002-12-17
CA2331879A1 (en)	1999-11-18
JP2000198772A (ja)	2000-07-18
CN1300285A (zh)	2001-06-20
IL139470A0 (en)	2001-11-25

Publication	Publication Date	Title
PT1077957E (pt)	2004-10-29	Derivados do acido oxi-iminoalcanoico
PT977733E (pt)	2003-12-31	Derivados de acido arilsulfonilamino-hidroxamico
PT1084102E (pt)	2004-02-27	Novos derivados do acido 3-aril-propionico e analogos
ATE269861T1 (de)	2004-07-15	Substituierte indolalkansäure
DK1003720T3 (da)	2004-05-10	Aryloxyarylsulfonylaminohydroxamsyrederivater
EE04772B1 (et)	2007-02-15	3-arüül-2-hüdroksüpropaanhappe derivaat (I)
ATE239005T1 (de)	2003-05-15	(4-sulfonylamino)-tetrahydropyran-4-carbonsäure hydroxamiden
PT1100769E (pt)	2003-04-30	Derivado do acido aminometilcarboxilico
DE69703385T2 (de)	2001-02-22	Alkoxyessigsäure-derivate
NO990821D0 (no)	1999-02-22	Arylsulfonylamino-hydroksaminsyre-derivater
DE69933283D1 (de)	2006-11-02	Photoaktivierbare nukleinsäure-derivate
IS5735A (is)	2000-11-28	Ný 3-arýl-2-hýdroxýprópínsýruafleiða III
ATE236136T1 (de)	2003-04-15	Benzosulfonderivate
ATE259810T1 (de)	2004-03-15	Phenyl-xanthinderivate
IS5562A (is)	2000-07-14	Nýjar díhýdroxýhexanósýru afleiður
PT915837E (pt)	2002-11-29	Derivados de acido glioxilico
ATE230734T1 (de)	2003-01-15	3-alkoxyisoxazol-4-yl-substituierte 2- aminocarbonsäurederivate
DK1115716T3 (da)	2003-02-24	2-phenylpyran-4-on-derivater
ATE233253T1 (de)	2003-03-15	Chromanderivate
DK1134219T3 (da)	2005-10-17	Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DK1060183T3 (da)	2003-08-11	5-deoxycytidinderivater
NO994386D0 (no)	1999-09-10	2-substituerte benzoylcykloalkyl-1-karboksylsyrederivater
PT929517E (pt)	2002-10-31	Derivados do acido hidroxamico
EE04061B1 (et)	2003-06-16	Metüleenbisfosfoonhappe derivaadid
DE59907635D1 (de)	2003-12-11	Pyrazolyldioxothiochromanoyl-derivate